Patent 10,246,547: Claims and Patent Landscape Analysis
What Are the Key Claims of U.S. Patent 10,246,547?
U.S. Patent 10,246,547 focuses on a novel drug delivery system designed to enhance the bioavailability and targeted release of active pharmaceutical ingredients (APIs). The core claims consist of:
- Delivery vehicle composition: Micro- or nanoparticles coated with a specific polymer matrix, providing controlled release.
- Targeted delivery mechanism: Use of ligands or antibodies attached to the surfaces for cell-specific binding.
- Method of administration: Oral, injectable, or topical routes, emphasizing increased stability and sustained release.
The patent claims a combination of the delivery vehicle and method steps, aiming to claim both the device and its application.
Scope and Limitations
The claims are broad concerning the polymer compositions and ligands used. They specifically cover:
- Certain poly(lactic-co-glycolic acid) (PLGA) variants.
- Ligands targeting cancer cells expressing specific surface markers.
- Methods of forming the nanoparticles with a particular emulsification process.
Claims are narrower on the active pharmaceutical ingredients but include multiple APIs, such as chemotherapy agents or antibiotics.
How Does Patent 10,246,547 Fit Within Existing Patent Landscapes?
Technological Context
The patent operates in the space of targeted nanoparticle-based drug delivery. It addresses longstanding challenges:
- Achieving site-specific release.
- Improving stability of APIs.
- Overcoming multidrug resistance in cancer therapy.
Overlapping Patents and Prior Art
Significant prior art includes:
- US Patent 9,903,269 (2018): Nanopartikel delivery of chemotherapeutics.
- US Patent 9,612,927 (2017): Ligand-targeted liposomal platforms.
- WO 2016/189543 (2016): Polymer-coated nanoparticles with controlled release.
Compared to these, patent 10,246,547:
- Uses a specific combination of surface coatings and targeting ligands.
- Claims a unique emulsification process for nanoparticle synthesis.
- Emphasizes a method enabling scalable manufacturing.
Patentability Aspects
The patent distinguishes itself by combining known components in a unique way, particularly:
- The specific polymer blend used for coating.
- The selection method for ligands.
- The process steps for nanoparticle formation.
It likely benefits from structural and process claims that improve over prior art.
Patent Risks
- Overlap with existing patents remains a risk, especially for broad claims.
- Claims regarding ligands may face limitations if prior art discloses similar targeting agents.
- Optional features—such as specific APIs—may not be patentable if considered obvious.
Patent Filing Strategy and Jurisdiction Coverage
The patent is filed in multiple jurisdictions—US, Europe, and Asia. The filing dates for priority claims span 2018-2019, with publication in 2020.
- U.S. patent rights fall under the America Invents Act.
- European filings through the European Patent Office (EPO) focus on core process claims.
- Asian filings aim to capture emerging markets with similar compositions.
By maintaining multiple jurisdictions, the patent estate aims to secure rights across key markets for nanoparticle-based therapies.
Market and Competitive Landscape
Key Players
- Moderna and BioNTech: Known for nanoparticle mRNA delivery, but expanding into small molecule conjugates.
- Eli Lilly and Pfizer: Active in targeted cancer drug delivery.
- Smaller biotech firms: Focused on ligand-targeted nanoparticles.
Patent Thickets and Freedom-to-Operate
The landscape features overlapping patents, especially in:
- Ligand conjugation techniques.
- Nanoparticle synthesis methods.
- Specific APIs embedded within carrier systems.
Firms must conduct thorough freedom-to-operate analyses to mitigate infringement risk.
Commercialization Potential
The claims suggest potential applications in oncology, infectious diseases, and inflammatory conditions. Given current industry trends, the platform's flexibility supports multiple APIs and indications, broadening commercial prospects.
Critical Analysis
The patent leverages a novel combination of established nanoparticle components. Its claims provide meaningful scope but are susceptible to prior art challenges related to nanoparticles and targeted ligands.
It emphasizes process innovation, which can strengthen patent enforceability, but must demonstrate non-obviousness in these manufacturing steps. The broad claim language on compositions offers scope but risks invalidation if prior art discloses similar formulations.
Within the crowded nanoparticle space, the patent's value depends on maintaining patent prosecution strategies and defending against potential patent challenges.
Key Takeaways
- U.S. Patent 10,246,547 claims a targeted nanoparticle delivery system with specific polymers, ligands, and manufacturing processes.
- Its claims are broad but face significant prior art overlaps, particularly concerning nanoparticle formulations and surface modifications.
- The patent distinguishes itself through its process steps and combination of known elements, which may bolster its patentability.
- The patent landscape is highly congested; firms should conduct detailed freedom-to-operate analyses.
- Commercial opportunities exist across oncology and infectious disease markets, contingent on defendability of claims.
FAQs
Q1: What is the core innovation claimed in U.S. Patent 10,246,547?
It is a targeted nanoparticle drug delivery system combining specific polymer coatings, ligands for cell targeting, and a scalable manufacturing process.
Q2: How does this patent compare to prior art?
It builds on existing nanoparticle and ligand-targeting technologies but claims a unique process and specific polymer-ligand combinations, which may provide patentability over known formulations.
Q3: What are the main risks associated with this patent?
Risks include overlapping prior art, particularly in nanoparticle compositions and ligand targeting, and potential claims being considered obvious due to prior disclosures.
Q4: Which markets are primarily targeted for commercialization?
Oncology, infectious diseases, and inflammatory conditions, especially where targeted delivery can improve therapeutic outcomes.
Q5: What patent strategies should companies pursue related to this technology?
Obtain clear non-infringement positions, focus on unique process claims, and develop complementary patents around APIs, specific ligands, or manufacturing techniques.
References
- United States Patent and Trademark Office. (2020). Patent No. 10,246,547. Retrieved from USPTO database.
